Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Capstone Therapeutics ( (CAPS) ) just unveiled an update.
On January 7, 2026, Capstone Holding Corp. received notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days, placing the company out of compliance with Nasdaq’s continued listing standards. The notification does not immediately affect trading of its shares, which continue to trade under the symbol “CAPS,” and Capstone has until July 6, 2026, to regain compliance, with the possibility of an additional 180-day extension if it meets other listing criteria; failure to do so could ultimately result in delisting, a development that would weigh on the stock’s liquidity and visibility for investors, while the company monitors its share price and considers options to restore compliance.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, shrinking margins, net losses) and high balance-sheet risk (negative equity), reinforced by bearish technicals (below major moving averages, negative MACD). Corporate events are a relative positive due to acquisition-driven growth initiatives and debt reduction, but they are not yet reflected in the underlying financial stability shown in the statements.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Average Trading Volume: 458,284
Technical Sentiment Signal: Sell
Current Market Cap: $6.12M
See more insights into CAPS stock on TipRanks’ Stock Analysis page.